Objective: Postpartum depression has been associated with parenting stress, impacting attachment and child development. However, the relation between antenatal depression or anxiety and postpartum parenting stress has not been investigated. We studied the effect of antenatal depression and anxiety and treatment with selective serotonin reuptake inhibitors and selective norepinephrine reuptake inhibitors (antidepressants [ADs]) on postpartum parenting stress.
P arenting stress is defined as the disparity between the demands associated with parenting and the perceived resources available to meet those demands, according to Abidin's 1 model. Parenting stress is considered to be a result of both parent and child characteristics as well as factors associated with caregiver-child interaction.
Postpartum depression has consistently been associated with increased levels of parenting stress.
2-4,5 Leigh and Milgrom 5 found that antenatal depression was the strongest predictor of postpartum depression, which in turn was the strongest predictor for parenting stress, suggesting that early identification and treatment of perinatal depression is important. Cornish et al 2 assessed 112 mother-infant dyads and found that mothers who had experienced postpartum depression reported increased levels of parenting stress at 15-months postpartum, compared with mothers who had never been depressed. Depressed mothers have been found to rate their children's temperament as more difficult than nondepressed mothers. 3 A study of 23 depressed postpartum mothers found that 78% of the sample reported clinical levels of parenting stress. 4 Further, this investigation demonstrated that treating the depression, either with an AD alone or in combination with CBT, resulted in decreased levels of parenting stress. In the postpartum population, those with mild to moderate depression have been shown to respond to CBT 6 and interpersonal therapy. 7 However, the effectiveness of psychotherapy alone in severe postpartum depression has not been investigated adequately with prospective controlled studies. Therefore, a methodologically sound study comparing pharmacological with psychological treatments is urgently warranted.
A combined approach of medication and psychotherapy is ideal. In our study, the focus was on the pharmaceutical treatment of depressed and (or) anxious antenatal women. In a recent prospective study evaluating predictors of parenting stress in parents of toddlers, Saisto et al 8 found pregnancyrelated anxiety, depression, personality factors, the child's temperament, and low self-estimated competence in routine caretaking measured at 2 to 3 months and 2 to 3 years after childbirth predicted parenting stress.
The literature demonstrates that perinatal depression is a continuum and many women experience onset during pregnancy, with symptoms continuing or worsening in the postpartum period. [9] [10] [11] In a recent meta-analysis, antenatal depression was found to be the strongest predictor of postpartum depression. 12 Moreover, depression during pregnancy has been shown to have adverse impacts on neonatal health, 13 ,14 which in turn have been associated with increased aggressive behaviours in children. 15 The fetal programming hypothesis explained by Van den Bergh et al 16 supports a link between antenatal maternal anxiety or stress and long-term effects in the child including cognitive, behavioural, and emotional problems. Compromised neonatal health and child behavioural problems have been linked with increased stress levels experienced by caregivers. 17, 18 Owing to these associations, it is logical to anticipate that antenatal depression and anxiety would have an impact on parenting stress.
In our study, we examined the impact of antenatal depression and anxiety on parenting stress. We predicted that as the symptoms of antenatal depression and anxiety worsened, the levels of parenting stress would increase. We expected that treatment with SSRIs or SNRIs during pregnancy would also predict lower levels of parenting stress, particularly if the women had been treated to remission. To our knowledge, no studies to date have investigated the relations between prenatal mood, pharmacologic treatment, and parenting stress.
Method

Participants
Data for our study was collected as part of a larger research project 19 investigating the impact of prenatal exposure to depressive illness and ADs on newborns. Participants were recruited into our study between 2001 and 2005 from the Reproductive Mental Health Program at British Columbia Women's Hospital in Vancouver, from referrals from physicians and midwives, and through advertisements placed in family physicians' offices, health units, and prenatal classes. Women were eligible for inclusion in our study if they were aged between 18 and 45 years; fluent in English; in their second or third trimester of pregnancy; and either depressed and treated with ADs (n = 39), depressed and not treated with ADs (n = 13), or not depressed and not on ADs (n = 42). Ninety-eight women were enrolled in the study, of which records for 19 women were not available for final analysis (dropped out or missing data). However, one woman was only missing her 3-month visit, therefore all of her remaining data was included for the final analysis. In total, 79 pregnant women were followed from their third trimester of pregnancy until 6-months postpartum. No significant differences between women who dropped out of the study and women who remained in the study on any of the demographic or clinical variables were observed (all Ps > 0.05) ( Table 1 ).
written informed consent was obtained from all participants, demographic information was obtained, and symptoms of depression and anxiety were assessed. The participants were followed at 3-and 6-months postpartum. During which depression and anxiety were re-evaluated and parenting stress was assessed. Information regarding medication use was collected in pregnancy and postpartum.
Measures
Depressive Symptoms
Depressive symptoms were assessed using the HDRS. 17 The HDRS is a 21-item clinician-administered inventory that measures severity of depressive symptoms in adults. Scores on the scale can range from 0 to 63, with higher scores indicative of higher levels of depression. 20 Scores ranging from 0 to 7 suggest no or minimal symptoms of depression, 8 to 17 indicate mild depression, 18 to 25 suggest moderate depression, and scores of 26 and above are associated with severe depression.
21
Anxiety Symptoms
The HARS is a 14-item clinician-administered scale that was used to assess symptoms of anxiety. 22 Scores on this scale have a possible range of 0 to 56, with higher scores on this measure associated with higher symptoms of anxiety in the patient. 18 Scores ranging from 0 to 7 suggest no or minimal symptoms of anxiety, while scores of 8 and above indicate the presence of anxiety. Thus a score of 8 is a clinically important cut-off point.
Parenting Stress
Parenting stress was measured with the PSI-SF.
1 This 36-item questionnaire is designed to provide an indication of the overall level of parenting stress and to identify parentchild relationships that are under stress and at risk of developing future problems. Total stress scores on this inventory reflect personal parental stress, stresses associated with caregiver-child interaction, and stresses relating to the child's behavioural characteristics. Total scores on this inventory can range from 36 to 180, with higher scores indicative of higher levels of stress. Raw scores above 90 indicate clinically significant levels of stress. 
Statistical Analysis
Preliminary analyses were conducted to compare mothers who dropped out of the study with those who persisted. In addition, Pearson correlation coefficients were used to examine the relations between depression and anxiety at each visit. Hierarchical linear regression was used to examine antenatal depression and anxiety and prenatal exposure to SSRIs and SNRIs as predictors of postpartum parenting stress controlling for maternal age and the number of children living within the home. Single motherhood was not included as a possible confounder as only 2 of the mothers were single parents. All analyses were performed using SPSS 16.0 (SPSS Inc, Chicago, IL).
Results
Eligible women for our study included those who were on ADs, regardless of whether or not they were symptomatic. Our sample was diverse in terms of depressive and anxiety symptoms at entry; some women were in remission on ADs at entry, while others demonstrated moderate to severe symptoms. Thus, for the group in remission, the scores on the HARS and HDRS were below the cut-off points for anxiety and depression. Scores on the HDRS ranged from 0 to 29, 0 to 21, and 0 to 33 during pregnancy, the third month postpartum, and the sixth month postpartum, respectively. The HARS scores ranged from 0 to 39 during the third trimester, 0 to 33 at 3-months postpartum, and 0 to 29 at 6-months postpartum. Women who experienced high levels of depression were also likely to experience high levels of anxiety (Table 2) , with correlations between the 2 measures at the same time point ranging from 0.85 to 0.90. Similarly, there was substantial variability in the degree of parenting stress experienced by the women in our study ( PSI-SF scores ranging from 37 to 128 at 3-months postpartum, and 38 to 114 at 6-months postpartum. Our study took place between 2002 and 2005, which was before the warning about paroxetine became available. Thus many of the women in our study were on paroxetine. Information regarding medications is presented in Table 4 .
The regression analyses found that both depression and anxiety (individually) during the third trimester of pregnancy were significant predictors of 3-and 6-month postpartum parenting stress after controlling for maternal age, the number of children in the home, and exposure to prenatal SSRIs and SNRIs (all Ps < 0.001) ( Table 3 ). Third trimester maternal mood accounted for between 13% and 22% of the variance in postpartum stress at 3 and 6 months, respectively. In contrast, exposure to prenatal SSRIs and SNRIs was not a significant predictor in any of the models (all Ps > 0.200) ( Table 3 ).
There were 41 patients exposed to ADs in pregnancy. Twenty patients on an AD achieved remission (HDRS = 7) in pregnancy and 21 did not. Patients treated to remission displayed average parenting stress scores about 1 standard deviation lower than those who did not achieve remission at 3-and 6-months postpartum (t = 3.32, df = 32, P = 0.002 and t = 2.52, df = 32, P = 0.017, respectively).
Discussion
Previous research has made it abundantly clear that postpartum depression has a negative impact on parenting stress. [2] [3] [4] What remains as yet unknown is whether pregnancyrelated mental illness impacts parental stress. Our study investigated this relation; we examined antenatal depression and anxiety and subsequent parenting stress, after controlling for AD use during pregnancy. Results indicate that increased symptoms of depression and anxiety during pregnancy were related to increased levels of postpartum parenting stress. These relations persisted even when controlling for postpartum depression and anxiety. Our findings suggest that women who experienced antenatal depression and anxiety are at increased risk for postnatal parenting stress, regardless of whether they were treated with an SSRI and (or) an SNRI AD during their pregnancy. Early intervention with the intention of treatment to remission is strongly warranted as those patients treated to remission showed significant reductions in the degree of parenting stress in the postpartum period.
There are several possible explanations for the relation between antenatal depression, anxiety, and postnatal parenting stress. Antenatal depression and anxiety have been shown to impact fetuses as well as early infant behaviour. Diego et al 23 found that babies born to mothers with antenatal depression spent more time fussing and crying and displayed more stress-related behaviours than infants born to mothers without antenatal depression. Babies born to depressed mothers have also been found to be more irritable and difficult to console, 24, 25 and are less attentive and responsive to facial expressions 26 than infants born to nondepressed mothers. In addition, depression during pregnancy can impact bonding between a mother and her fetus, 27 thereby affecting their relationship postpartum.
In our study, a small percentage of women did not show remission of depression or anxiety despite treatment with ADs. In fact, this group demonstrated increased levels of parenting stress in the postpartum period. Prior research has indicated that not all women who are depressed and treated with medications during pregnancy will experience a complete remission of their symptoms. 28, 29 Cohen et al 28 reported that 26% of 82 women who were treated to euthymia with medications prior to pregnancy, and maintained their medications throughout pregnancy, still experienced a relapse in symptoms after conception. Therefore, some depressed women, despite treatment with ADs continued to be symptomatic in pregnancy; even if there was a reduction in severity, these prenatal symptoms continued to have an impact on parenting stress in the postpartum period. It is important to note that recent evidence from the Sequenced Treatment Alternatives to Relieve Depression 30 clinical trial from the National Institute of Mental Health shows that the success rate of ADs in the general population is somewhere between 50% to 66% and that not all who are on medication show remission of depression or anxiety.
In our study we also found that many women refused to increase their medication dosage during pregnancy. A recent qualitative study investigating the reasons why women adhere while others decline AD use in pregnancy showed that many women do not want to expose the fetus to medications during pregnancy. 31 Consequently, they chose to remain symptomatic rather than receive treatment with medication. In addition, our study further showed that many of the women already on an AD refused to increase their dose for fear of increased drug exposure to the fetus. Our clinical observation shows that despite dose increase, not all women remit with AD treatment in pregnancy. Specifically, women with comorbid symptoms of anxiety disorder such as obsessive-compulsive disorder and generalized anxiety disorder inevitably need higher doses of ADs plus the addition of an anti-anxiety and or antipsychotic agent for symptom relief. CBT and other therapeutic strategies are additional options for those with comorbid symptoms. Thus treatment to remission is frequently challenging if not an impossible for this group who dread exposing the fetus to medication and resist pharmacologic intervention.
High levels of parenting stress have been shown to negatively affect the parent-child relationship. Gelfand et al 32 found that blind raters judged depressed mothers who were experiencing higher levels of parenting stress as less competent and less affectively appropriate with their babies. Another study by Teti et al 33 reported parenting stress negatively impacts the quality of mothers' interactions with their children. Additionally, high levels of stress associated with parenting can lead to insecure attachment in children. 34, 35 Clearly, parenting stress has been associated with negative consequences for the relationship between a child and his or her caregiver. Mash and Johnston 36 found high levels of parenting stress contributed to the disruption of family systems and indirectly affected children's development. Insecure attachment has been associated with developmental difficulties in children in social, psychological, behavioural, Table 3 Multiple regression analyses to predicting 3-and 6 -month postpartum parenting stress and cognitive realms. 37, 38 Therefore, it is important to identify antecedents of parenting stress as early as possible to promote healthy maternal-child relationships and child development.
Parenting stress can be long-lasting, extending past the postpartum period, even after the remission of depression. 2 Cornish et al 2 found that mothers who experience brief postnatal depression report increased levels of parenting stress in the second postpartum year even if their depression remitted. This lends further support to identifying and treating depression during the entire perinatal period. Even with treatment in a timely manner, antenatal depression may continue, and often worsens in the postpartum unless remission is achieved.
Our study suggests that antenatal depression and anxiety contribute to increased maternal postpartum parenting stress. Parenting stress should be included routinely in clinical assessments of women at risk. Limitations of our study include a small sample size and predominately women of Caucasian background, which may limit the generalization of its findings. Moreover, we did not account for factors such as marital instability, lack of support, financial stressors, and adverse social circumstances which could have potentially affected their treatment outcome. More research is needed in this area to further replicate our findings and introduce appropriate antenatal screening strategies and treatment recommendations to avoid adverse outcomes in newborns, toddlers, and youth. Résultats : La dépression et l'anxiété prénatales du troisième trimestre étaient toutes deux des prédicteurs significatifs du stress parental à 3 et 6 mois du postpartum, après contrôle de l'âge maternel, du nombre d'enfants, et de l'exposition aux AD prénataux (tous les P < 0,001). La dépression au troisième trimestre représentait de 13 % à 22 % de la variance du stress postpartum à 3 et 6 mois. L'utilisation prénatale d'AD n'était pas un prédicteur significatif dans aucun des modèles (tous les P > 0,2). Vingt mères sur 41 utilisant des AD ont atteint la rémission (HDRS = 7) durant la grossesse et avaient des scores moyens de stress parental d'environ 1 écart type plus faible que celles n'ayant pas de rémission à 3 et à 6 mois du postpartum (t = 3,32, dl = 32, P = 0,002 et t = 2,52, dl = 32, P = 0,02, respectivement).
Conclusions :
Nos résultats indiquent que la dépression et l'anxiété prénatales affectent directement le stress parental postpartum, sans égard au traitement aux AD prénatal. La maladie mentale maternelle durant la grossesse est un important prédicteur du stress parental postpartum. La reconnaissance précoce et le traitement vers la rémission sont essentiels.
